Buy Crypto Markets Spot FuturesGOLD Earn Event Center

enGene Therapeutics Inc. (ENGN)

NASDAQ

$8.00

$-0.14

(-1.72%)

enGene Therapeutics Inc. (ENGN) Live Price Chart

Page last updated: 2026-04-24 23:59:00

Key Market Data

Market Cap	$545.29M
Open	$8.02
High	$52.84
Low	$2.65
Previous Close	$8.14
Price Change	$-0.14
Percentage Change	-1.72%
Volume	212K

enGene Therapeutics Inc. (ENGN) Stock Price Today

enGene Therapeutics Inc. (ENGN) is currently trading at $8.00 as of 2026-04-24 23:59:00, reflecting a -1.72% move ($-0.14) from the previous close.

In the short term, the stock has returned +25.59% over the past four weeks. Over the last 12 months, enGene Therapeutics Inc. has recorded a +105.66% price change, indicating a Strong performance relative to the broader market.

enGene Therapeutics Inc. (ENGN) 7-Day Stock Price Changes

Over the past seven days, enGene Therapeutics Inc. has traded within a short-term range shaped by market sentiment in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. During this period, the stock moved from its previous closing price of $8.05 to the latest recorded price of $8.00, reflecting an intraday change of -1.72%. Daily movements highlight shifts in trading volume (211,947), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, ENGN has delivered a +25.59% return over the past month and a +105.66% change in the last 12 months, indicating a Strong trend relative to its broader sector peers.

How to Buy enGene Therapeutics Inc. (ENGN)

You can buy and trade ENGN on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for ENGN and Execute Your Trade

Open the trading page, enter ENGN in the search bar, select the amount of ENGN you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is enGene Therapeutics Inc. (ENGN)?

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

enGene Therapeutics Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	82
Sector	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Website	https://www.engene.com

Frequently Asked Questions (FAQ)

1.What is the current share price of enGene Therapeutics Inc.?

The latest trading price for enGene Therapeutics Inc. (Common Stock) is $ 8.00, compared with a previous closing price of $ 8.14. That means the stock has moved -1.72% so far today. Intraday price updates and recent trading activity for ENGN can be tracked on the live chart and quote section on this page.

2.Is enGene Therapeutics Inc. stock going up or down?

Looking at recent performances, ENGN has returned +25.59% over the past month, +1.14% over the last six months and +105.66% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe Strong price momentum for enGene Therapeutics Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does ENGN currently sit relative to its 52-week high and low?

In the most recent 52-week period, enGene Therapeutics Inc. has traded between a low of $ 2.65 and a high of $ 12.25. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether ENGN is currently nearer the top or the bottom of its one-year trading band.

4.How is enGene Therapeutics Inc. classified by sector and industry?

enGene Therapeutics Inc. is classified in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. In practice, this means enGene Therapeutics Inc. is grouped with other companies that serve similar end-markets and operate under comparable competitive and regulatory conditions. For investors, knowing ENGN’s sector helps with portfolio diversification, peer comparisons, and understanding how broader trends affecting the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector could influence enGene Therapeutics Inc.’s performance.

5.Where is enGene Therapeutics Inc. listed and how large is it by market value?

enGene Therapeutics Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 545.29M, the company is classified as a Small-cap stock. Market cap gives a quick sense of enGene Therapeutics Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does ENGN's EPS tell investors about its profitability?

Trailing-twelve-month EPS of $ -1.83 summarises how much profit enGene Therapeutics Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track enGene Therapeutics Inc.'s financial performance over time?

To follow enGene Therapeutics Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how ENGN is performing and how the market is responding.

8.When is enGene Therapeutics Inc. expected to report earnings?

enGene Therapeutics Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for ENGN, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in enGene Therapeutics Inc.'s earnings reports?

enGene Therapeutics Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether ENGN is meeting, beating or missing expectations.

10.How can I stay informed about enGene Therapeutics Inc.'s results and guidance?

You can stay up to date on enGene Therapeutics Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for ENGN on this page helps you see how new information is being reflected in the stock.

11.Does enGene Therapeutics Inc. pay a regular cash dividend to its shareholders?

enGene Therapeutics Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of 0 at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor ENGN's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for ENGN?

Based on the latest earnings data, ENGN has a dividend yield of 0 and a dividend payout ratio of 0. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether enGene Therapeutics Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings enGene Therapeutics Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is enGene Therapeutics Inc.?

enGene Therapeutics Inc. is a publicly traded company in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry within the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is ENGN valued in terms of P/E ratio and EPS?

enGene Therapeutics Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of $ -1.83. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of enGene Therapeutics Inc.'s earnings. Comparing ENGN's P/E and EPS to those of other BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Applied Digital Corporation

Top Gainers

Browse today's leading gainers in the US stock market

MaxLinear, Inc.

MXL

Atomera Incorporated

ATOM

Elong Power Holding Limited

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

SOL

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

ENGN-to-USD Calculator

Amount

ENGN

USD

1 ENGN = 8 USD